(efgartigimod alfa + hyaluronidase (human recombinant))

all catalysts(0)

nothing on the calendar yet

News(3)

• Argenx jumps on Phase 3 data for blockbuster Vyvgart
  The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
  biopharma_dive · 14h ago
• Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
  Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug
  endpoints · 19h ago
• Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
  The star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
  biospace · 21d ago